PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges
PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...
Why PTC Therapeutics (PTCT) Stock Is Rallying Today
PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113
Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...